Price reference for Denosumab

Denosumab (Denosumab) is a drug used to treat bone-related diseases and belongs to the antimetabolite drug class. Its main role is to increase bone density, reduce fracture risk and manage bone-related diseases by inhibiting RANKL (receptor-activated nuclear factor kappa B ligand), a key molecule in the bone resorption process.

The generic drug Desosomet is already on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of about 1,600 yuan. Please consult the local hospital pharmacy or medical insurance bureau for specific prices and reimbursement policies. There are only denosumab original drugs available abroad, mainly the Turkish version of the American Amgen original drug. The price is about 1,300 yuan, and the ingredients and efficacy are consistent with the domestic original drug.

Denosumab is a monoclonal antibody specifically designed to targetRANKL, a protein that promotes bone resorption. By binding to RANKL, denosumab can prevent its binding to bone cells, thereby inhibiting the activity of osteoclasts, slowing down the bone resorption process, increasing bone density, and reducing the risk of fractures.

Denosumab is mainly used in menopausal women and the elderly to increase bone density and reduce the risk of fractures. Used in certain cancer patients to slow or reduce the progression of bone metastases and relieve bone pain.

Denosumab is usually given to patients by subcutaneous injection. Treatment of osteoporosis is generally injected every six months. Treatment plans for cancer bone metastasis may vary depending on the patient's specific situation and be formulated by the doctor as needed.

The use of denosumab may be associated with some side effects, including headache, nausea, diarrhea, bone pain, muscle pain, etc. Serious side effects such as hypocalcemia and skin infection are rare but should be taken with caution.

Denosumab is a powerful drug with important value in the treatment and prevention of bone-related diseases. Patients should receive treatment under the guidance of a doctor and undergo regular examinations to ensure optimal treatment effects and safety.